Big pharma can only see the benefit of R&D for wealthy markets

There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries
Read more: https://www.theguardian.com/commentisfree/2019/may/05/big-pharma-can-only-see-the-benefit-of-r-and-d-for-rich-markets?source=Snapzu